RedHill Biopharma Ltd.

NASDAQ (USD): RedHill Biopharma Ltd. (RDHL)

Last Price

0.393

Today's Change

-0.002 (0.50%)

Day's Change

0.37 - 0.408

Trading Volume

1,343,178

Overview

Market Cap

12 Million

Shares Outstanding

31 Million

Avg Volume

342,861

Avg Price (50 Days)

0.44

Avg Price (200 Days)

0.68

PE Ratio

0.10

EPS

4.00

Earnings Announcement

18-Jun-2024

Previous Close

0.40

Open

0.39

Day's Range

0.37 - 0.4078

Year Range

0.257 - 3.28

Trading Volume

1,343,178

Price Change Highlight

1 Day Change

-0.63%

5 Day Change

-1.77%

1 Month Change

-14.59%

3 Month Change

-21.97%

6 Month Change

-71.94%

Ytd Change

-73.09%

1 Year Change

-78.53%

3 Year Change

-99.86%

5 Year Change

-99.86%

10 Year Change

-99.95%

Max Change

-99.91%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment